Healthcare 2030: facing up to a pharma future
This article was originally published in Scrip
Four key opinion leaders discuss a utopian vision of healthcare up to 2030. A future the pharmaceutical industry must buy into, face up to, or risk being left behind.
You may also be interested in...
Third quarter earnings show Gilead’s Immunomedics buy paid off, but filgotinib’s path may narrow. The HIV and HCV franchises picked up from their COVID-19 lull.
US pharmacy group says that 10 to 12 states have indicated through an informal survey that they do not have the manpower or funding to implement the US FDA’s final MOU on inordinate compounding. They say what is at stake in these states is patient access to compounded medicines.
Mayo Clinic announces AI-based partnerships with Google and voice-analysis company Vocalis Health this week.